Chronic Lymphocytic Leukemia
📧 Sign up to get email alerts when something new happens for Chronic Lymphocytic Leukemia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2025-11-26Clinical Trial Update: In Vivo Metabolic Profiling of CLL (Chronic Lymphocytic Leukemia)
This clinical trial update describes an in vivo metabolic profiling study for Chronic Lymphocytic Leukemia led by University of Wisconsin–Ma…
-
CLINICAL_TRIALS other · 2025-11-26Clinical Trial Update: Long-Term Follow-up of Patients Treated With Miltenyi Cell and Gene Therapies [NA]
Clinical trial update for Miltenyi Biomedicine's cell and gene therapy program indicates ongoing recruitment and planned long-term follow-up…
-
CLINICAL_TRIALS trial_result · 2025-11-25Clinical Trial Update: A Study to Assess Frequency of Undetectable Minimal Residual Disease (uMRD) in Adult Participants With Chronic Lymphocytic Leukemia (CLL) Receiving Oral Venetoclax Tablets ± Intravenously (IV) Infused Rituximab in Routine Clinical Practice in Japan
A completed clinical trial evaluating how often adult chronic lymphocytic leukemia patients in Japan achieve undetectable minimal residual d…
-
CLINICAL_TRIALS research · 2025-11-25Clinical Trial Update: Venetoclax as Consolidation in CLL Patients Treated With BTK Inhibitor Monotherapy [Phase 2]
A Phase 2 trial is evaluating venetoclax as consolidation therapy in chronic lymphocytic leukemia or small lymphocytic lymphoma patients on …
-
CLINICAL_TRIALS research · 2025-11-21Clinical Trial Update: Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL [Phase 2]
Phase 2 clinical trial evaluating venetoclax with either ibrutinib or acalabrutinib in high-risk chronic lymphocytic leukemia is currently r…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2025-11-21Clinical Trial Update: Watch and Wait or Worry and Wait in Indolent Lymphoma
An ongoing clinical trial at Seoul National University Hospital is evaluating watchful waiting versus proactive worry-and-wait strategies in…
-
CLINICAL_TRIALS research · 2025-11-21Clinical Trial Update: ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (APEX-03) [Phase 2, Phase 3]
APEX-03 is a Phase 2/3 clinical trial evaluating ICP-248 in combination with orelabrutinib for treatment-naïve chronic lymphocytic leukemia …
-
CLINICAL_TRIALS research · 2025-11-19Clinical Trial Update: Acalabrutinib in Combination With Venetoclax for the Treatment of Refractory or Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, The AVENUE-2 Trial [Phase 2]
The AVENUE-2 Phase 2 trial investigates acalabrutinib in combination with venetoclax for patients with refractory or recurrent chronic lymph…
-
CLINICAL_TRIALS trial_result · 2025-11-18Clinical Trial Update: Identification of Biomarkers That Are Predictive of Early Ibrutinib Treatment Failure in High Risk TP53 Mutated Chronic Lymphocytic Leukemia
The update reports on biomarkers that may predict early failure of ibrutinib therapy in high-risk TP53-mutated chronic lymphocytic leukemia.
-
CLINICAL_TRIALS research · 2025-11-14Clinical Trial Update: A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies [Phase 1, Phase 2]
A phase 1/2 clinical trial evaluating CTX112 in relapsed or refractory B-cell malignancies is currently recruiting.
-
CLINICAL_TRIALS trial_result · 2025-11-12Clinical Trial Update: Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer [Phase 1]
A Phase 1 trial evaluating natural killer cell therapy in combination with Interleukin-2 and the TGF-beta receptor I inhibitor vactosertib f…
-
CLINICAL_TRIALS research · 2025-11-10Clinical Trial Update: huCART19-IL18 in CD19+ Cancers [Phase 1]
Phase 1 clinical trial of huCART19-IL18 for CD19+ cancers is currently ACTIVE_NOT_RECRUITING, sponsored by the University of Pennsylvania, i…
-
CLINICAL_TRIALS research · 2025-11-10Clinical Trial Update: Long-term Follow-up Study of Patients Receiving CAR-T Cells
This clinical trial update outlines a long-term follow-up study of patients who received CAR-T cell therapy. Sponsored by the Medical Colleg…
-
CLINICAL_TRIALS trial_result · 2025-11-10Clinical Trial Update: Phase 1 Study of BAFF CAR-T Cells (LMY-920) for Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma [Phase 1]
Phase 1 study of BAFF CAR-T cells (LMY-920) for relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma is curren…
-
CLINICAL_TRIALS trial_result · 2025-11-06Clinical Trial Update: Phase II Study of Combined Pirtobrutinib, Venetoclax and Obinutuzumab (PVO) Time-limited Treatment for Patients With Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL). [Phase 2]
Phase II clinical trial update for a time-limited combination therapy (pirtobrutinib, venetoclax, obinutuzumab) in recurrent Chronic Lymphoc…
-
CLINICAL_TRIALS research · 2025-11-06Clinical Trial Update: Ibrutinib With or Without Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia [Phase 2]
A Phase 2 trial is evaluating ibrutinib with or without rituximab in patients with relapsed chronic lymphocytic leukemia and related lymphop…
-
CLINICAL_TRIALS research · 2025-11-06Clinical Trial Update: Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma [Phase 1]
Phase 1 clinical trial evaluating a triplet regimen of tafasitamab, acalabrutinib, and obinutuzumab for previously untreated chronic lymphoc…
-
CLINICAL_TRIALS research · 2025-11-04Clinical Trial Update: Tafasitamab and Zanubrutinib for the Treatment of Patients With Newly Diagnosed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, TaZA CLL Study [Phase 2]
Phase 2 TaZA CLL study evaluating the combination of tafasitamab and zanubrutinib for newly diagnosed chronic lymphocytic leukemia or small …
-
CLINICAL_TRIALS trial_result · 2025-11-03Clinical Trial Update: Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies [Phase 2]
Phase 2 trial evaluating nivolumab in patients with hematologic malignancies after CAR-T therapy; results have been posted with the study cu…
-
CLINICAL_TRIALS trial_result · 2025-10-30Clinical Trial Update: Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in With High-Risk Hematologic Malignancies [Phase 2]
Phase 2 trial evaluating reduced-intensity conditioning before allogeneic donor stem cell transplantation in patients with high-risk hematol…
-
CLINICAL_TRIALS research · 2025-10-30Clinical Trial Update: Two Step Haplo With Radiation Conditioning [Phase 2]
Phase 2 clinical trial update describing two-step haploidentical transplantation with radiation conditioning for hematologic diseases, curre…
-
EMA approval · 2025-10-24EMA Authorised: Venclyxto (venetoclax) — AbbVie Deutschland GmbH & Co. KG
The European Medicines Agency authorised Venclyxto (venetoclax) for chronic lymphocytic leukemia (B-cell lineage) with AbbVie Deutschland as…
-
CLINICAL_TRIALS research · 2025-10-23Clinical Trial Update: Adding Pirtobrutinib to the Usual Treatment for People With Newly Diagnosed Richter Transformation, The PIRAMID Trial [Phase 3]
Phase 3 PIRAMID trial evaluating adding pirtobrutinib to standard therapy for newly diagnosed Richter transformation (transformed CLL/SLL to…
-
FDA approval · 2025-10-21FDA Approved: IMBRUVICA — Supplemental Application (Pharmacyclics LLC)
FDA approved a supplemental application for IMBRUVICA (ibrutinib) submitted by Pharmacyclics LLC.
-
CLINICAL_TRIALS research · 2025-10-21Clinical Trial Update: Kappa-CD28 T Lymphocytes, Chronic Lymphocytic Leukemia, B-cell Lymphoma or Multiple Myeloma, CHARKALL [Phase 1]
Phase 1 clinical trial update for Kappa-CD28 T lymphocytes in chronic lymphocytic leukemia, B-cell lymphoma, and multiple myeloma. The study…